Exact Mass: 518.2701952
Exact Mass Matches: 518.2701952
Found 148 metabolites which its exact mass value is equals to given mass value 518.2701952
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Blumenol C O-[rhamnosyl-(1->6)-glucoside]
Blumenol C O-[rhamnosyl-(1->6)-glucoside] is found in fruits. Blumenol C O-[rhamnosyl-(1->6)-glucoside] is a constituent of quince (Cydonia vulgaris) leaves
triglyceride palmitate
PA(2:0/20:3(6,8,11)-OH(5))
PA(2:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(6,8,11)-OH(5)/2:0)
PA(20:3(6,8,11)-OH(5)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(6,8,11)-OH(5)/2:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Cys Ile Gln Arg
Cys Ile Arg Gln
Cys Leu Gln Arg
Cys Leu Arg Gln
Cys Gln Ile Arg
Cys Gln Leu Arg
Cys Gln Arg Ile
Cys Gln Arg Leu
Cys Arg Ile Gln
Cys Arg Leu Gln
Cys Arg Gln Ile
Cys Arg Gln Leu
Asp Glu Lys Lys
Asp Lys Glu Lys
Asp Lys Lys Glu
Glu Asp Lys Lys
Glu Lys Asp Lys
Glu Lys Lys Asp
Gly Met Arg Arg
Gly Arg Met Arg
Gly Arg Arg Met
Ile Cys Gln Arg
Ile Cys Arg Gln
Ile Gln Cys Arg
Ile Gln Arg Cys
Ile Arg Cys Gln
Ile Arg Gln Cys
Lys Asp Glu Lys
Lys Asp Lys Glu
Lys Glu Asp Lys
Lys Glu Lys Asp
Lys Lys Asp Glu
Lys Lys Glu Asp
Leu Cys Gln Arg
Leu Cys Arg Gln
Leu Gln Cys Arg
Leu Gln Arg Cys
Leu Arg Cys Gln
Leu Arg Gln Cys
Met Gly Arg Arg
Met Asn Arg Val
Met Asn Val Arg
Met Arg Gly Arg
Met Arg Asn Val
Met Arg Arg Gly
Met Arg Val Asn
Met Val Asn Arg
Met Val Arg Asn
Asn Met Arg Val
Asn Met Val Arg
Asn Arg Met Val
Asn Arg Val Met
Asn Val Met Arg
Asn Val Arg Met
Gln Cys Ile Arg
Gln Cys Leu Arg
Gln Cys Arg Ile
Gln Cys Arg Leu
Gln Ile Cys Arg
Gln Ile Arg Cys
Gln Leu Cys Arg
Gln Leu Arg Cys
Gln Arg Cys Ile
Gln Arg Cys Leu
Gln Arg Ile Cys
Gln Arg Leu Cys
Arg Cys Ile Gln
Arg Cys Leu Gln
Arg Cys Gln Ile
Arg Cys Gln Leu
Arg Gly Met Arg
Arg Gly Arg Met
Arg Ile Cys Gln
Arg Ile Gln Cys
Arg Leu Cys Gln
Arg Leu Gln Cys
Arg Met Gly Arg
Arg Met Asn Val
Arg Met Arg Gly
Arg Met Val Asn
Arg Asn Met Val
Arg Asn Val Met
Arg Gln Cys Ile
Arg Gln Cys Leu
Arg Gln Ile Cys
Arg Gln Leu Cys
Arg Arg Gly Met
Arg Arg Met Gly
Arg Val Met Asn
Arg Val Asn Met
Val Met Asn Arg
Val Met Arg Asn
Val Asn Met Arg
Val Asn Arg Met
Val Arg Met Asn
Val Arg Asn Met
Blumenol C O-[rhamnosyl-(1->6)-glucoside]
Betamethasone butyrate propionate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
[(2R)-1-acetyloxy-3-phosphonooxypropan-2-yl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate
[(2R)-2-acetyloxy-3-phosphonooxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate
longirostrerone C
An azaphilone that is 9,9a-dihydro-6H-furo[2,3-h]isochromene-6,8(6aH)-dione substituted by a 6-methyl-2-oxocyclohex-3-en-1-yl group at position 3, a methyl group at position 6a and a 4,6,8-trimethyldeca-2,4-dienoyl group at position 9. Isolated from Chaetomium longirostre, it exhibits cytotoxic and antimalarial activities.
RF9 (hydrochloride)
RF9 hydrochloride is a potent and selective Neuropeptide FF receptor antagonist, with Ki values of 58 and 75 nM for hNPFF1R and hNPFF2R, respectively[1][2].
2-({1-hydroxy-2-[(2-methylbut-3-en-2-yl)amino]-3-phenylpropylidene}amino)-n-[2-methyl-1-(1,3-thiazol-2-yl)propyl]-3-phenylpropanimidic acid
C30H38N4O2S (518.2715327999999)
(6ar,9s,9ar)-6a-methyl-3-[(1s,6s)-6-methyl-2-oxocyclohex-3-en-1-yl]-9-[(2e)-4,6,8-trimethyldeca-2,4-dienoyl]-9h,9ah-furo[2,3-h]isochromene-6,8-dione
(2s)-2-{[(2s)-1-hydroxy-2-[(2-methylbut-3-en-2-yl)amino]-3-phenylpropylidene]amino}-n-[(1s)-2-methyl-1-(1,3-thiazol-2-yl)propyl]-3-phenylpropanimidic acid
C30H38N4O2S (518.2715327999999)
(4r,7r,8r,15r,18r,19r)-4,7,15,18-tetramethyl-12-{[(2s)-2-(prop-1-en-2-yl)-2,3-dihydro-1-benzofuran-5-yl]methyl}-3,5,14,16-tetraoxapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁵,¹⁹]icosa-1(13),2(10),11-trien-11-ol
4-{2,6,6-trimethyl-4-[(3,4,5-trihydroxy-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-2-yl)oxy]cyclohex-1-en-1-yl}butan-2-one
n-[2-({[(1r,2r,3s,5s,9s,10s,13s,17s)-11-ethyl-9-methoxy-4-oxo-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-7-en-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid
C31H38N2O5 (518.2780577999999)